At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02629 MIRXES-B
Not Yet Opened 03-04 16:08:16
13.990
-1.250
-8.20%
High15.420
Low13.790
Vol4.30M
Open15.400
D1 Closing15.240
Amplitude10.70%
Mkt Cap4.17B
Tradable Cap4.17B
Total Shares298.00M
T/O61.06M
T/O Rate1.44%
Tradable Shares298.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
MIRXES-B (02629) Signs Memorandum of Understanding with AHLL for Strategic Collaboration
MiRXES Holding Company Limited is a micro ribonucleic acid (miRNA) technology company specializing in early cancer detection and precision medicine. It develops and commercializes accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Its segments include Infectious diseases and Early detection and precision multi-omics. Its solutions include cancer screening; clinical sequencing; cancer treatment selection, and infectious diseases. Its core product (namely, GASTROClear), two other commercialized products (namely, LUNGClear and Fortitude), and six product candidates at pre-clinical stage. GASTROClear is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. LUNGClear, its lung cancer screening product candidate, is a detection panel consisting of miRNA biomarkers discovered and verified in multi-center studies. It offers complete COVID-19 testing solutions.